Xenon Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of December 2025: 35.63%

Xenon Pharmaceuticals Inc (XENE) has an Asset Resilience Ratio of 35.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read XENE current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$349.72 Million

Cash + Short-term Investments

Total Assets

$981.67 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Xenon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Xenon Pharmaceuticals Inc for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Xenon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xenon Pharmaceuticals Inc (XENE) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$349.72 Million	35.63%
Total Liquid Assets	$349.72 Million	35.63%

Asset Resilience Insights

Very High Liquidity: Xenon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.63% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Xenon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Xenon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Argen-X F:1AE	Biotechnology	25.67%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.21%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.48%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	70.49%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for Xenon Pharmaceuticals Inc (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Xenon Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	35.63%	$349.72 Million	$981.67 Million	-25.04pp
2024-12-31	60.67%	$484.19 Million	$798.14 Million	+9.94pp
2023-12-31	50.73%	$489.44 Million	$964.80 Million	-20.19pp
2022-12-31	70.92%	$534.85 Million	$754.15 Million	+5.17pp
2021-12-31	65.75%	$376.09 Million	$572.01 Million	-4.02pp
2020-12-31	69.77%	$131.99 Million	$189.19 Million	-9.18pp
2019-12-31	78.95%	$116.60 Million	$147.70 Million	+36.84pp
2018-12-31	42.11%	$51.55 Million	$122.43 Million	-8.15pp
2017-12-31	50.26%	$23.18 Million	$46.12 Million	-19.46pp
2016-12-31	69.72%	$47.05 Million	$67.49 Million	--
2015-12-31	0.00%	$0.00	$63.95 Million	--
2014-12-31	13.74%	$12.02 Million	$87.42 Million	-7.04pp
2013-12-31	20.79%	$11.33 Million	$54.49 Million	--

pp = percentage points

About Xenon Pharmaceuticals Inc

NASDAQ:XENE USA Biotechnology

Market Cap

$4.34 Billion

Market Cap Rank

#4703 Global

#1517 in USA

Share Price

$56.13

Change (1 day)

+0.16%

52-Week Range

$28.49 - $62.76

All Time High

$62.76